이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Trastuzumab Deruxtecan(DS-8201a) 대 전이되었거나 외과적으로 제거할 수 없는 HER2-낮은 유방암에 대한 연구자의 선택 [DESTINY-Breast04]

2026년 9월 1일 업데이트: Daiichi Sankyo

DS-8201a, 항 HER2-항체 약물 접합체(ADC)의 3상, 다기관, 무작위, 공개, 능동 제어 시험, HER2가 낮고 절제 불가능 및/또는 전이성 유방암 피험자를 위한 의사의 선택 치료 비교

This study will compare DS-8201a to physician choice standard treatment.

Participants must have HER2-low breast cancer that has been treated before.

Participants' cancer:

  • Cannot be removed by an operation
  • Has spread to other parts of the body

연구 개요

상태

완전한

정황

개입 / 치료

상세 설명

This is a randomized, 2-arm, Phase 3, open-label, multicenter study to compare the safety and efficacy of trastuzumab deruxtecan versus the physician's choice (2:1) in HER2-low, unresectable and/or metastatic breast cancer participants.

The Sponsor proposes to define a new HER2-low population in this trial including tumors with IHC 1+ and IHC 2+/ISH- HER2 expression.

연구 유형

중재적

등록 (실제)

557

단계

  • 3단계

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 장소

      • Athens, 그리스, 15125
        • Athens Medical Center
      • Athens, 그리스, 11528
        • General Hospital of Athens "Alexandra"
      • Athens, 그리스, 14564
        • General Oncology Hospital of Kifissia " Agioi Anargyroi"
      • Heraklion, 그리스, 71110
        • University General Hospital of Heraklion
      • Larissa, 그리스, 41110
        • University General Hospital of Larissa
      • Thessaloniki, 그리스, 54622
        • Bioclinic Thessaloniki
      • Thessaloniki, 그리스, 54645
        • Euromedica General Clinic Thessaloniki
      • Thessaloniki, 그리스, 56429
        • General Hospital Papageorgiou
      • Thessaloniki, 그리스, 57001
        • Interbalkan Hospital of Thessaloniki
      • Kaohsiung City, 대만, 807
        • Kaohsiung Medical University Chung-Ho Memorial Hospital
      • Tainan, 대만, 704
        • National Cheng Kung University Hospital
      • Taipei, 대만, 100
        • National Taiwan University Hospital
      • Daegu, 대한민국, 41404
        • Kyungpook National University Chilgok Hospital
      • Seoul, 대한민국, 03080
        • Seoul National University Hospital
      • Seoul, 대한민국, 05505
        • Asan Medical Center
      • Seoul, 대한민국, 06351
        • Samsung Medical Center
      • Seoul, 대한민국, 06591
        • The Catholic University of Korea, Seoul St. Mary's Hospital
      • Seoul, 대한민국, 120-752
        • Severance Hospital, Yonsei University Health System
    • Gyeonggi-do
      • Goyang-si, Gyeonggi-do, 대한민국, 10408
        • National Cancer Center
      • Incheon, Gyeonggi-do, 대한민국, 22332
        • Inha University Hospital
      • Seongnam-si, Gyeonggi-do, 대한민국, 13620
        • Seoul National University Bundang Hospital
      • Suwon, Gyeonggi-do, 대한민국, 16499
        • Ajou University Hospital
    • North Chungcheong
      • Cheongju-si, North Chungcheong, 대한민국, 361-711
        • Chungbuk National University Hospital
    • Baden-Wurttemberg
      • Heidelberg, Baden-Wurttemberg, 독일, 69120
        • Universitaetsklinikum Heidelberg
    • Bavaria
      • Munich, Bavaria, 독일, 81377
        • Klinikum der Universitaet Muenchen - Campus Grosshardern
      • Moscow, 러시아 제국, 115478
        • FSBSI "Russian Oncological Scientific Center n.a. N.N. Blokhin"
      • Moscow, 러시아 제국, 143423
        • SBIH of Moscow City "Moscow City Oncology Hospital №62" of Moscow Healthcare Departement
      • Yaroslavl, 러시아 제국, 150054
        • SBIH of Yaroslavl Region "Regional Clinical Oncological Hospital"
    • Arizona
      • Chandler, Arizona, 미국, 85224
        • Ironwood Cancer & Research Centers - Chandler II
      • Gilbert, Arizona, 미국, 85234
        • Banner MD Anderson Cancer Center
      • Goodyear, Arizona, 미국, 85338
        • Cancer Treatment Centers of America at Western Regional Medical Center
    • California
      • Los Angeles, California, 미국, 90095
        • UCLA School of Medicine
      • Palo Alto, California, 미국, 94305
        • Stanford Cancer Institute
      • Redondo Beach, California, 미국, 90277
        • Cancer Care Associates Medical Group, Inc. TORI
      • San Francisco, California, 미국, 94158
        • University of California at San Francisco (PARENT)
    • Connecticut
      • Norwich, Connecticut, 미국, 06360
        • Eastern Connecticut Hematology/Oncology Assoc.
    • Delaware
      • Newark, Delaware, 미국, 19713
        • Christiana Care Health Services, Inc.
    • Florida
      • Boca Raton, Florida, 미국, 33426
        • Sylvester Comprehensive Cancer Center - Deerfield Beach
      • Fort Myers, Florida, 미국, 33916
        • Florida Cancer Specialists (South Region)
      • Hollywood, Florida, 미국, 33021
        • Memorial Healthcare System MRH Cancer Center
      • Orlando, Florida, 미국, 32806
        • Orlando Health, Inc.
      • Tampa, Florida, 미국, 33139
        • Moffitt Cancer Center -Tampa
    • Georgia
      • Newnan, Georgia, 미국, 30263
        • Cancer Treatment Centers of America-Georgia
    • Illinois
      • Chicago, Illinois, 미국, 60637
        • University of Chicago Medical Center
      • Zion, Illinois, 미국, 60099
        • Cancer Treatment Centers of America
    • Kansas
      • Wichita, Kansas, 미국, 67214
        • Cancer Center of Kansas
    • Louisiana
      • New Orleans, Louisiana, 미국, 70115
        • Touro Infirmary
    • Massachusetts
      • Boston, Massachusetts, 미국, 02215
        • Dana-Farber Cancer Institute
    • Michigan
      • Detroit, Michigan, 미국, 48202
        • Henry Ford Hospital
    • Missouri
      • Kansas City, Missouri, 미국, 64111
        • Saint Luke's Hospital of Kansas City
    • New Jersey
      • Livingston, New Jersey, 미국, 07039
        • Saint Barnabas Medical Center
    • New York
      • New York, New York, 미국, 10016
        • New York University Medical Center
      • New York, New York, 미국, 10065
        • Memorial Sloan Kettering Hospital
      • New York, New York, 미국, 10065
        • Weill Cornell Medicine Breast Center
    • Ohio
      • Cleveland, Ohio, 미국, 44195
        • The Cleveland Clinic Foundation
    • Oregon
      • Portland, Oregon, 미국, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Pittsburgh, Pennsylvania, 미국, 15212
        • Allegheny General Hospital
      • Pittsburgh, Pennsylvania, 미국, 15219
        • University of Pittsburgh Medical Center Health System
    • South Carolina
      • Greenville, South Carolina, 미국, 29601
        • St Francis Hospital
    • Tennessee
      • Knoxville, Tennessee, 미국, 37909
        • Brig Center for Cancer Care and Survivorship
      • Memphis, Tennessee, 미국, 38120
        • Baptist Cancer Center
      • Nashville, Tennessee, 미국, 37201
        • Tennessee Oncology - Skyline Satellite
    • Texas
      • Dallas, Texas, 미국, 75234
        • BloomTrials Clinical Research, LLC
      • Houston, Texas, 미국, 77030
        • The Methodist Hospital Research Institute
      • Houston, Texas, 미국, 77030
        • University of Texas M. D. Anderson Cancer Center - Investigational Cancer Therapeutics
    • Virginia
      • Fairfax, Virginia, 미국, 22031
        • Virginia Cancer Specialists
      • Brussels, 벨기에, 1000
        • Institut Jules Bordet
      • Brussels, 벨기에, 1090
        • Universitair Ziekenhuis Brussel
      • Brussels, 벨기에, 1200
        • Cliniques Universitaires Saint-Luc
      • Leuven, 벨기에, 3000
        • UZ Leuven
      • Loverval, 벨기에, 6280
        • Grand Hôpital de Charleroi
      • Namur, 벨기에, 5000
        • CHU UCL Namur
      • Tournai, 벨기에, 7500
        • Centre Hospitalier Wallonie picarde - Site IMC
      • Solna, 스웨덴, 17176
        • Karolinska universitetssjukhuset - Solna
      • Sundsvall, 스웨덴, 85186
        • Länssjukhuset Sundsvall-Härnösand
      • Uppsala, 스웨덴, 75185
        • Akademiska Sjukhuset
      • Aarau, 스위스, 5000
        • Hirslanden Medical Center
      • Basel, 스위스, 4031
        • Universitaetsspital Basel
      • Chur, 스위스, 7000
        • Kantonsspital Graubuenden
      • Lausanne, 스위스, 1011
        • Centre Hospitalier Universitaire Vaudois
      • Sankt Gallen, 스위스, 9007
        • Kantonsspital St. Gallen
      • Winterthur, 스위스, 8401
        • Kantonsspital Winterthur
      • Zurich, 스위스, 8091
        • Universitaetsspital Zuerich
      • Barcelona, 스페인, 08036
        • Hospital Clinic de Barcelona
      • Barcelona, 스페인, 08035
        • Hospital Universitari Vall d'Hebron
      • Barcelona, 스페인, 08023
        • Hospital Quironsalud Barcelona
      • Barcelona, 스페인, 08003
        • Hospital del Mar
      • Madrid, 스페인, 28034
        • Hospital Universitario Ramon y Cajal
      • Madrid, 스페인, 28040
        • Hospital Universitario Clinico San Carlos
      • Madrid, 스페인, 28034
        • Hospital Ruber Internacional
      • Madrid, 스페인, 28033
        • MD Anderson Cancer Centre
      • Málaga, 스페인, 29010
        • Hospital Clinico Universitario Virgen de la Victoria
      • Seville, 스페인, 41009
        • Hospital Universitario Virgen Macarena
      • Seville, 스페인, 41013
        • Hospital Universitario Virgen del Rocio
      • Valencia, 스페인, 46014
        • Hospital General Universitario de Valencia
      • Valencia, 스페인, 46009
        • Instituto Valenciano de Oncologia IVO
    • Barcelona
      • L'Hospitalet de Llobregat, Barcelona, 스페인, 08908
        • ICO l'Hospitalet - Hospital Duran i Reynals
    • Guipuzcoa
      • San Sebastián, Guipuzcoa, 스페인, 20014
        • Hospital Universitario Donostia
    • La Coruña
      • A Coruña, La Coruña, 스페인, 15006
        • Complejo Hospitalario Universitario A Coruña
    • Tenerife
      • San Cristóbal de La Laguna, Tenerife, 스페인, 38320
        • Hospital Universitario de Canarias
    • Vizcaya
      • Bilbao, Vizcaya, 스페인, 48013
        • Hospital de Basurto
    • Cornwall
      • Truro, Cornwall, 영국, TR1 3LJ
        • Royal Cornwall Hospital
    • Greater London
      • London, Greater London, 영국, NW3 2QG
        • Royal Free Hospital
      • London, Greater London, 영국, EC1M 6BQ
        • Queen Mary University of London
      • London, Greater London, 영국, NW1 2PG
        • University College London Hospitals
    • Lothian Region
      • Edinburgh, Lothian Region, 영국, EH4 2XU
        • Western General Hospital
    • Nottinghamshire
      • Nottingham, Nottinghamshire, 영국, NG5 1PB
        • Nottingham University Hospitals City Campus
    • Surrey
      • Guildford, Surrey, 영국, GU2 7XX
        • Royal Surrey County Hospital
      • Innsbruck, 오스트리아, 6020
        • Medizinische Universität Innsbruck
      • Linz, 오스트리아, 4020
        • Kepler Universitätsklinikum
      • Salzburg, 오스트리아, 5020
        • LKH - Universitätsklinikum der PMU Salzburg
      • Vienna, 오스트리아, 1090
        • AKH - Medizinische Universität Wien (4305)
      • Wels, 오스트리아, 4600
        • Klinikum Wels-Grieskirchen GmbH
      • Haifa, 이스라엘, 3109601
        • Rambam Health Care Center
      • Jerusalem, 이스라엘, 9103102
        • Shaare Zedek Medical Center
      • Jerusalem, 이스라엘, 9112001
        • Hadassah University Hospital - Ein Kerem
      • Petah Tikva, 이스라엘, 49100
        • Rabin Medical Center-Beilinson Campus
      • Ramat Gan, 이스라엘, 52363
        • Chaim Sheba Medical Center
      • Rehovot, 이스라엘, 7610001
        • Kaplan Medical Center
      • Safed, 이스라엘, 13100
        • Ziv Medical Center
      • Tel Aviv, 이스라엘, 6423906
        • Tel Aviv Sourasky Medical Center
      • Bologna, 이탈리아, 40138
        • Azienda Ospedaliera Universitaria Policlinico Sant'Orsola Malpighi
      • Brescia, 이탈리아, 25100
        • Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia (Presidio Spedali Civili)
      • Catania, 이탈리아, 95125
        • Azienda Ospedaliera Univ. Policlinico Gaspare Rodolico
      • Catanzaro, 이탈리아, 88100
        • Azienda Ospedaliero Universitaria Mater Domini-Campus Universitario
      • Milan, 이탈리아, 20141
        • IEO Istituto Europeo di Oncologia
      • Naples, 이탈리아, 80131
        • Istituto Nazionale Tumori Fondazione G. Pascale
      • Rimini, 이탈리아, 47923
        • Ospedale degli Infermi
      • Roma, 이탈리아, 00168
        • Fondazione Policlinico Universitario Agostino Gemelli IRCCS
      • Roma, 이탈리아, 00133
        • Azienda Ospedaliera Universitaria Policlinico Tor Vergata
    • Lecce
      • Tricase, Lecce, 이탈리아, 73039
        • Azienda Ospedaliera Card. G. Panico
    • Milano
      • Monza, Milano, 이탈리아, 20900
        • Azienda Socio Sanitaria Territoriale di Monza (Presidio San Gerardo)
      • Rozzano, Milano, 이탈리아, 20089
        • Istituto Clinico Humanitas
    • Verona
      • Negrar, Verona, 이탈리아, 37024
        • Ospedale Sacro Cuore Don Calabria
    • Aichi-ken
      • Nagoya, Aichi-ken, 일본, 464-8681
        • Aichi Cancer Center Hospital
    • Chiba
      • Kashiwa-shi, Chiba, 일본, 277-8577
        • National Cancer Center Hospital East
    • Ehime
      • Matsuyama, Ehime, 일본, 791-0280
        • NHO Shikoku Cancer Center
    • Fukuoka
      • Fukuoka, Fukuoka, 일본, 811-1395
        • NHO Kyushu Cancer Center
    • Fukushima
      • Fukushima, Fukushima, 일본, 960-1295
        • Fukushima Medical University Hospital
    • Hiroshima
      • Hiroshima, Hiroshima, 일본, 730-8518
        • Hiroshima City Hiroshima Citizens Hospital
    • Hokkaido
      • Sapporo, Hokkaido, 일본, 003-0804
        • NHO Hokkaido Cancer Center
    • Hyōgo
      • Nishinomiya-shi, Hyōgo, 일본, 663-8501
        • Hyogo College of Medicine Hospital
    • Kagoshima-ken
      • Kagoshima, Kagoshima-ken, 일본, 892-0833
        • Hakuaikai Sagara Hospital
    • Kanagawa
      • Isehara, Kanagawa, 일본, 259-1193
        • Tokai University Hospital
      • Yokohama, Kanagawa, 일본, 241-8515
        • Kanagawa Cancer Center
    • Osaka
      • Osaka, Osaka, 일본, 540-0006
        • NHO Osaka National Hospital
    • Osakasayama-shi
      • Onohigashi, Osakasayama-shi, 일본, 589-8511
        • Kindai University Hospital
    • Saitama
      • Kitaadachi-gun, Saitama, 일본, 362-0806
        • Saitama Cancer Center
    • Shizuoka
      • Sunto-gun, Shizuoka, 일본, 411-8777
        • Shizuoka Cancer Center
    • Tokyo-To
      • Kōtoku, Tokyo-To, 일본, 135-8550
        • Cancer Institute Hospital of JFCR
      • Minatoku, Tokyo-To, 일본, 105-8470
        • Toranomon Hospital
      • Shinagawa-Ku, Tokyo-To, 일본, 142-8666
        • Showa University Hospital
    • Anhui
      • Hefei, Anhui, 중국, 230001
        • Anhui Provincial Hospital
    • Beijing Municipality
      • Beijing, Beijing Municipality, 중국, 100853
        • Chinese PLA General Hospital
      • Beijing, Beijing Municipality, 중국, 100021
        • Cancer Hospital Chinese Academy of Medical Sciences
    • Fujian
      • Fuzhou, Fujian, 중국, 350025
        • Fuzhou General Hospital of Nanjing Military Area Command of Chinese PLA
    • Guangdong
      • Guangzhou, Guangdong, 중국, 510120
        • Sun Yat-sen Memorial hospital, Sun Yat-sen University
    • Heilongjiang
      • Harbin, Heilongjiang, 중국, 150081
        • Harbin Medical University Cancer Hospital
    • Hubei
      • Wuhan, Hubei, 중국, 430079
        • Hubei Cancer Hospital
    • Jiangsu
      • Nanjing, Jiangsu, 중국, 210008
        • The Affiliated Drum Tower Hospital of Nanjing University
    • Jilin
      • Changchun, Jilin, 중국, 130000
        • The First Hospital of Jilin University
      • Changchun, Jilin, 중국, 130012
        • Jilin Cancer Hospital
    • Liaoning
      • Shenyang, Liaoning, 중국, 110042
        • Liaoning Cancer Hospital & Institute
    • Ningxia Hui
      • Yinchuan, Ningxia Hui, 중국, 750004
        • General Hospital of Ningxia Medical University
    • Shandong
      • Linyi, Shandong, 중국, 276001
        • Linyi Cancer Hospital
    • Shanghai Municipality
      • Shanghai, Shanghai Municipality, 중국, 200080
        • Shanghai General Hospital
      • Shanghai, Shanghai Municipality, 중국, 20032
        • Fudan University Shanghai Cancer Center
    • Sichuan
      • Chengdu, Sichuan, 중국, 610041
        • West China Hospital, Sichuan University
    • Zhejiang
      • Hangzhou, Zhejiang, 중국, 310022
        • Zhejiang Cancer Hospital
      • Hangzhou, Zhejiang, 중국, 310016
        • Sir Run Run Shaw Hospital, Zhejiang University, School of Medicine
    • Alberta
      • Calgary, Alberta, 캐나다, T2N4N2
        • Tom Baker Cancer Center
    • Ontario
      • Toronto, Ontario, 캐나다, M4N 3M5
        • Toronto Sunnybrook Hospital
    • Quebec
      • Montreal, Quebec, 캐나다, H2W 1S6
        • McGill University - Dept. Oncology Clinical Research Program
      • Braga, 포르투갈, 4710-243
        • Hospital de Braga
      • Guimarães, 포르투갈, 4835-044
        • Centro Hospitalar do Alto do Ave, EPE
      • Lisbon, 포르투갈, 1649-035
        • Centro Hospitalar de Lisboa Norte, E.P.E. - Hospital de Santa Maria
      • Lisbon, 포르투갈, 1400-038
        • Fundação Champalimaud
      • Matosinhos Municipality, 포르투갈, 4464-509
        • Unidade Local de Saúde de Matosinhos, EPE (Hospital Pedro Hispano)
      • Porto, 포르투갈, 4200-072
        • Instituto Português de Oncologia do Porto Francisco Gentil, EPE
      • Porto, 포르투갈, 4099-001
        • Centro Hospitalar do Porto, E.P.E. - Hospital de Santo António
      • Santa Maria da Feira, 포르투갈, 4520-211
        • Centro Hospitalar de Entre o Douro e Vouga, E.P.E - Hospital de São Sebastião
      • Vila Nova de Gaia, 포르투갈, 4434-502
        • Centro Hospitalar Vila Nova de Gaia/Espinho, E.P.E
      • Vila Real, 포르투갈, 5000-508
        • Centro Hospitalar de Trás-os-Montes e Alto Douro, EPE
      • Paris, 프랑스, 75020
        • Hopital Tenon
      • Paris, 프랑스, 75005
        • Institut Curie - site de Paris
    • Bouches-du-Rhône
      • Marseille, Bouches-du-Rhône, 프랑스, 13009
        • Institut Paoli Calmettes
    • Calvados
      • Caen, Calvados, 프랑스, 14076
        • Centre François Baclesse
    • Cotes d'Armor
      • Plérin, Cotes d'Armor, 프랑스, 22190
        • CARIO - Centre Armoricain de Radiothérapie, Imagerie médicale et Oncologie
    • Finistere
      • Brest, Finistere, 프랑스, 29609
        • CHU Brest - Hôpital Morvan
    • Gironde
      • Bordeaux, Gironde, 프랑스, 33076
        • Institut Bergonié
    • Herault
      • Montpellier, Herault, 프랑스, 34070
        • Clinique Clementville
      • Montpellier, Herault, 프랑스, 34298
        • Institut Régional du Cancer de Montpellier
    • Ille Et Vilaine
      • Rennes, Ille Et Vilaine, 프랑스, 35042
        • CRLCC Eugene Marquis
    • Loire Atlantique
      • Saint-Herblain, Loire Atlantique, 프랑스, 44805
        • ICO - Site René Gauducheau
    • Loiret
      • Le Puy-en-Velay, Loiret, 프랑스, 43012
        • Centre Hospitalier Emile Roux
    • Maine Et Loire
      • Angers, Maine Et Loire, 프랑스, 49055
        • ICO - Site Paul Papin
    • Nord
      • Valenciennes, Nord, 프랑스, 59322
        • Centre Hospitalier Valenciennes
    • Paris
      • Paris, Paris, 프랑스, 75475
        • Hôpital Saint-Louis - Paris
    • Sarthe
      • Le Mans, Sarthe, 프랑스, 72015
        • Clinique Victor Hugo - Centre Jean Bernard
    • Vaculuse
      • Avignon, Vaculuse, 프랑스, 84918
        • Institut Sainte Catherine
    • Val De Marne
      • Saint-Mandé, Val De Marne, 프랑스, 94160
        • Hôpital d'Instruction des Armees Begin*
      • Villejuif, Val De Marne, 프랑스, 94805
        • Institut Gustave Roussy
      • Budapest, 헝가리, 1097
        • Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet
      • Budapest, 헝가리, 1122
        • Orszagos Onkologiai Intezet
      • Debrecen, 헝가리, 4032
        • Debreceni Egyetem
      • Gyula, 헝가리, 5700
        • Bekes Megyei Kozponti Korhaz Pandy Kalman Tagkorhaza
      • Nyíregyháza, 헝가리, 4400
        • SzSzB Megyei Korhazak es Egyetemi Oktatokorhaz
      • Szolnok, 헝가리, 5004
        • Jasz-Nagykun-Szolnok Megyei Hetenyi Geza Korhaz-Rendelointezet

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Is the age of majority in their country

  • Has pathologically documented breast cancer that:

    1. Is unresectable or metastatic
    2. Has low-HER2 expression defined as IHC 2+/ISH- or IHC 1+ (ISH- or untested)
    3. Is HR-positive or HR-negative
    4. Has progressed on, and would no longer benefit from, endocrine therapy
    5. Has been treated with 1 to 2 prior lines of chemotherapy/adjuvant in the recurrent or metastatic setting
    6. Was never previously HER2-positive (ICH 3+ or ISH+) on prior pathology testing (per American Society of Clinical Oncology-College of American Pathologists [ASCO-CAP] guidelines)
  • Has documented radiologic progression (during or after most recent treatment)

  • Has adequate archival tumor samples available or is wiling to provide fresh biopsies prior to randomization for:

    1. assessment of HER2 status
    2. assessment of post-treatment status
  • Has at least 1 measurable lesion per Response Evaluation Criteria In Solid Tumors 1.1

  • Has protocol-defined adequate cardiac, bone marrow, renal, hepatic and blood clotting functions

  • Male and female participants of reproductive/childbearing potential, agrees to follow instructions for method(s) of contraception and agrees to avoid preserving ova or sperm for at least 4.5 months after treatment (or longer, per locally approved labels)

Exclusion Criteria:

  • Is ineligible for all options in the physician's choice arm
  • Has breast cancer ever assessed with high-HER2 expression
  • Has previously been treated with any anti-HER2 therapy, including an antibody drug conjugate
  • Has uncontrolled or significant cardiovascular disease
  • Has spinal cord compression or clinically active central nervous system metastases
  • Has history of (noninfectious) interstitial lung disease (ILD)/pneumonitis that required steroids, has current ILD/pneumonitis, or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening
  • Has any medical history or condition that per protocol or in the opinion of the investigator is inappropriate for the study

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 치료
  • 할당: 무작위
  • 중재 모델: 병렬 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Trastuzumab deruxtecan

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to DS8201a

DS-8201a is a lyophilized powder reconstituted into a sterile aqueous solution (100 mg/5 mL) to be administered intravenously

다른 이름들:
  • DS-8201a
활성 비교기: Physician's Choice

HER2-low, unresectable, and/or metastatic breast cancer participants previously treated with chemotherapy randomized to Physician's choice from the following options:

  • Capecitabine
  • Eribulin
  • Gemcitabine
  • Paclitaxel
  • Nab-paclitaxel

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

Administered according to label, as one option for Physician's Choice (determined before randomization)

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
기간: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

2차 결과 측정

결과 측정
측정값 설명
기간
전체 생존 이벤트 수(사망)
기간: 무작위 배정일로부터 어떠한 원인으로 인한 사망일까지, 최대 약 3년
무작위 배정일로부터 어떠한 원인으로 인한 사망일까지, 최대 약 3년
Progression-free Survival (PFS) Based on Blinded Independent Central Review (BICR) in Participants With HER2-low Breast Cancer (All Patients) Regardless of Hormone Receptor Status
기간: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on blinded independent central review (BICR) according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
기간: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment in the hormone receptor-positive cohort according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Progression-free Survival Based on Investigator Assessment in Participants With HER2-low Breast Cancer (All Patients)
기간: From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years

Progression-free survival (PFS), defined as at least a 20% increase in the sum of diameters of target lesions, was assessed from the date of randomization to the date of the first radiographic disease progression or death due to any cause, whichever came first. PFS was based on investigator assessment according to modified Response Evaluation Criteria in Solid Tumors (mRECIST) version 1.1. Median PFS was from Kaplan-Meier analysis. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of randomization to the earliest date of the first objective documentation of radiographic disease progression or death due to any cause, up to approximately 3 years
Overall Survival (OS) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
기간: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Overall Survival (OS) in All Patients
기간: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

Overall survival (OS) was defined as the time from the date of randomization to the date of death due to any cause. If there was no death reported for a participant before the data cutoff for OS analysis, OS was censored at the last contact date at which the participant was known to be alive.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
기간: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Best Overall Response and Confirmed Objective Response Rate (ORR) in Participants With HER2-low Breast Cancer (All Patients)
기간: From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years

Best overall response rate and confirmed objective response rate (ORR) were assessed by blinded independent central review (BICR) and investigator assessment. Complete response (CR) was defined as a disappearance of all target lesions, partial response (PR) was defined as at least a 30% decrease in the sum of diameters of target lesions, and stable disease (SD) was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for progressive disease (PD; at least a 20% increase in the sum of diameters of target lesions. Confirmed ORR was defined as the number of participants with complete and partial responses and confirmed by a second assessment.

From screening and every 6 weeks up to withdrawal of subject consent, progressive disease (PD), or unacceptable toxicity, up to approximately 3 years
Duration of Response in the Hormone Receptor-Positive Cohort in Participants With HER2-low Breast Cancer
기간: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years
Duration of Response in Participants With HER2-low Breast Cancer (All Patients)
기간: From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

Duration of Response (DoR) is defined as the date of the first documented objective response (complete response [CR] or partial response [PR]) to the first documented disease progression or death, whichever occurs first. DoR was based on blinded independent central review (BICR) and investigator assessment. Median was from Kaplan-Meier estimate. Confidence interval for median was computed using the Brookmeyer-Crowley method.

From the date of the first documented objective response (CR or PR) to the first documented disease progression or death, whichever occurs first, up to approximately 3 years

기타 결과 측정

결과 측정
측정값 설명
기간
All-Cause Mortality
기간: From the date of randomization up to the date of death due to any cause, up to approximately 3 years

All-cause mortality is defined as all anticipated and unanticipated deaths due to any cause, with the number and frequency of such events by arm or comparison group of the clinical study.

From the date of randomization up to the date of death due to any cause, up to approximately 3 years

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 연구 책임자: Global Clinical Leader, Daiichi Sankyo

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (실제)

2018년 12월 27일

기본 완료 (실제)

2022년 1월 11일

연구 완료 (실제)

2026년 5월 19일

연구 등록 날짜

최초 제출

2018년 11월 6일

QC 기준을 충족하는 최초 제출

2018년 11월 6일

처음 게시됨 (실제)

2018년 11월 7일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 9월 28일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 9월 1일

마지막으로 확인됨

2026년 9월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • DS8201-A-U303
  • 2018 (미국 NIH 보조금/계약)
  • 2018-003069-33 (EudraCT 번호)
  • 184223 (레지스트리 식별자: JAPIC CTI)
  • DESTINY-B04 (기타 식별자: Daiichi Sankyo and AstraZeneca)

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual participant data (IPD) and applicable supporting clinical trial documents may be available upon request at https://vivli.org/. In cases where clinical trial data and supporting documents are provided pursuant to our company policies and procedures, Daiichi Sankyo will continue to protect the privacy of our clinical trial participants. Details on data sharing criteria and the procedure for requesting access can be found at this web address: https://vivli.org/ourmember/daiichi-sankyo/

IPD 공유 기간

Studies for which the medicine and indication have received European Union (EU) and United States (US), and/or Japan (JP) marketing approval on or after 01 January 2014 or by the US or EU or JP Health Authorities when regulatory submissions in all regions are not planned and after the primary study results have been accepted for publication.

IPD 공유 액세스 기준

Formal request from qualified scientific and medical researchers on IPD and clinical study documents from clinical trials supporting products submitted and licensed in the United States, the European Union and/or Japan from 01 January 2014 and beyond for the purpose of conducting legitimate research. This must be consistent with the principle of safeguarding study participants' privacy and consistent with provision of informed consent.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • ICF

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

예

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .